Harbour BioMed Strengthens Board with CFO and Legal Chief Appointments
Event summary
- Harbour BioMed appoints Youchen Chen (CFO) and Ian Y. Liu (Global Head of Legal) as Executive Directors effective August 27, 2026.
- Chen brings 15 years of biopharma finance experience, including roles at Credit Suisse and a radiopharmaceutical startup.
- Liu has 20 years of legal and biopharma experience, previously at law firms Finnegan and K&L Gates, and Simcere Pharmaceutical.
- Appointments aim to strengthen alignment between board and management for global strategic execution.
The big picture
The appointments signal Harbour BioMed's push to tighten governance as it scales globally, with both executives bringing deep industry experience. The move comes amid heightened competition in antibody therapeutics, where strategic partnerships and regulatory navigation are critical. The company aims to position itself as a leader by 2028, leveraging its proprietary technology platforms and AI-driven drug discovery.
What we're watching
- Governance Dynamics
- How the dual appointments will impact board-management collaboration and strategic decision-making.
- Execution Risk
- Whether Harbour BioMed can sustain its ambitious 2028 goal of becoming a leading global biopharmaceutical group.
- Strategic Partnerships
- The pace at which Chen and Liu can leverage their networks to secure additional global partnerships.